Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus;Limitaciones de los fármacos dependientes de insulina para el tratamiento de la diabetes mellitus tipo 2

Medicina Clinica

Volumn 141, Issue SUPPL. 2, 2013, Pages 20-25

  Valerón, Pino Fuente ^a   De Pablos Velasco, Pedro L ^a,b  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

Author keywords

Insulin; Oral antidiabetics; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ARTICLE; BLADDER CANCER; BLOOD GLUCOSE MONITORING; BODY WEIGHT DISORDER; CANCER RISK; DRUG EFFICACY; DRUG SAFETY; EDEMA; FRACTURE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; WEIGHT GAIN;

ANTIDIABÉTICOS ORALES; DIABETES TIPO 2; INSULIN; INSULINA; ORAL ANTIDIABETICS; TYPE 2 DIABETES;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FRACTURES, SPONTANEOUS; GASTROINTESTINAL DISEASES; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS; WEIGHT GAIN;

EID: 84893129231     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(13)70059-9     Document Type: Article

References (26)

1. Turner RC, Cull CA, Frighi V, Holman RR; for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiples therapies(UKPDS49). JAMA. 1999;281:2005-12.
2. Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35:446-54.
3. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP; for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin or glyburidemonotherapy. N Engl J Med. 2006;355:2427-43.
4. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetic drugs: retrospective cohort study using UK general practice research database. BMJ. 2009;339:b4731.
5. Wright AD, Cull CA, Macleod KM, Holman RR; for the UKPDS Group. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, orinsulin for 6 years from diagnosis: UKPDS 73. J Diabetes Complications. 2006;20:395-401.
6. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.
7. McCormack J, Johns K, Tildesley H. Metformins contraindications should be contraindicated. CMAJ. 2005;173:502-4.
8. American Diabetes Association. Metformin shown to be safe and effective inpregnancy. 65th Annual Scientific Sessions, San Diego, CA; 10-14 June 2005. Bayside Tribune p. 1.
9. Holman RR. Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective. Metabol Clin Exp. 2006;55 Suppl 1:S2-5.
10. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS26: Sulphonylurea failure in non-insulin dependent diabetic patients over six years. Diabet Med. 1998;15:297-303.
11. University Group Diabetes Program. Effects of hypoglycaemic agents on vascular complication in patients with adult-onset diabetes. III: clinical implications of UGDP results. JAMA. 1971;218:1400-10.
12. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 2007;335:497-507.
13. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119-24.
14. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170:1191-201.
15. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, DAgostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima media thickness in type 2 diabetes: a randomized trial CHICAGO. JAMA. 2006;296: 2572-81.
16. Nissen SE, Nichols SJ, Wolski K, Nesto R, Kupfer S, Pérez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561-73.
17. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type-2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomized controlled trial. Lancet. 2005;366:1279-89.
18. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry J, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone. Diabetes Care. 2011;34:916-22.
19. Caisse National dAssurance Maladie. Risque de cancer de la vessie chez les personnes diabétiques traitées par pioglitazone en France: une étude de cohorte sur les données du SNIIRAM et du PMSI. Saint Denis: Afssaps; 2011.
20. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012;98:159-63.
21. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of non insulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303:1410-18.
22. Amori RE, Lau J, Pittas A. Efficacy and safety of incretin therapy in type 2 diabetes. Systematic review and meta-analysis. JAMA. 2007;298:194-206.
23. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide vers us sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, openlabel trial. Lancet. 2010;375:1447-56.
24. Garber A, Henry R, Ratner R, García-Hernández PA, Rodríguez-Pattzi H, Olveraálvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-81.
25. Victoza® (liraglutide injection): human relevance of rodentthyroid C-celltumors [consultado 26-4-2011]. Disponible en: http://www.fda.gov.
26. Wenten M, Bloomgren GL. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med. 2012;29:1412-8.